Ambrisentan

BreastfeedingPediatric
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Conivaptan, Cyclosporine, CYP2C19 inducers or inhibitors, CYP3A4 inducers or inhibitors, Dasatinib, Deferasirox, Grapefruit Juice, St John's Wort

PREGNANCY CATEGORY: X

Under investigation for treating COVID-19

See adverse reactions attributed to class:

Antihypertensive

Endothelin receptor (ETR) antagonist

Also contra-indicated in patients with idiopathic pulmonary fibrosis.

CONTRA-INDICATED IN PREGNANCY

See full prescribing information for complete boxed warning.

Edema / fluid retention (see also peripheral edema) 

(2017): Takahashi T+, Clin Drug Investig Dec, Epub ahead of print3%

(2017): Vachiery JL+, J Heart Lung Transplant 36(4), 39925%

(2012): Rubin LJ, Life Sci 91(13-14), 517

(2012): Shapiro S+, Am J Cardiol 110(9), 1373

Facial edema 

(2017): Takahashi T+, Clin Drug Investig Dec, Epub ahead of print3%

Flushing / rubefaction 4%

(package insert)

Peripheral edema (see also edema) 17%

(2017): Takahashi T+, Clin Drug Investig Dec, Epub ahead of print4%

(2016): Wei A+, J Am Heart Assoc 5(11), Epub [REVIEW]

(2015): Galie N+, N Engl J Med 373(9), 834 (with tadalafil)

(2015): Tran K+, CADTH Therapeutic Reviews Mar, Epub [REVIEW]

(2014): Kholdani CA+, Vasc Health Risk Manag 10, 665>10% (passim)

(2012): Badesch DB+, Cardiovasc Ther 30(2), 93

(2012): Vizza CD+, Expert Opin Drug Saf 11(6), 1003

(2009): Kingman M+, Expert Opin Pharmacother 10 (11), 1847

(2009): Minniti CP+, Br J Haematol 147 (5), 737

Rash 

(2009): Minniti CP+, Br J Haematol 147 (5), 737

Epistaxis (nosebleed) 

(2017): Takahashi T+, Clin Drug Investig Dec, Epub ahead of print2%

Nasal congestion 6%

(2015): Galie N+, N Engl J Med 373(9), 834 (with tadalafil)

(2012): Vizza CD+, Expert Opin Drug Saf 11(6), 1003

Palpitation 5%

(package insert)

Headache 15%

(2017): Takahashi T+, Clin Drug Investig Dec, Epub ahead of print4%

(2015): Galie N+, N Engl J Med 373(9), 834 (with tadalafil)

(2012): Badesch DB+, Cardiovasc Ther 30(2), 93

(2009): Minniti CP+, Br J Haematol 147 (5), 737

Abdominal pain 3%

(package insert)

Constipation 4%

(package insert)

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI) 

(2014): Kholdani CA+, Vasc Health Risk Manag 10, 665<3% (passim)

(2014): Murdaca G+, Expert Opin Drug Saf 13(3), 295

(2012): Rubin LJ, Life Sci 91(13- 14), 517

Anemia 

(2017): Takahashi T+, Clin Drug Investig Dec, Epub ahead of print5%

(2017): Vachiery JL+, J Heart Lung Transplant 36(4), 39914%

(2015): Galie N+, N Engl J Med 373(9), 834 (with tadalafil)

(2015): Tran K+, CADTH Therapeutic Reviews Mar, Epub [REVIEW]

(2014): Kholdani CA+, Vasc Health Risk Manag 10, 6653–10% (passim)

Nasopharyngitis 3%

(package insert)

Sinusitis 3%

(package insert)

Adverse effects 

(2015): Aversa M+, Drug Saf 38(5), 419 [REVIEW]



Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ambrisentan in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Adverse reactions attributed to entire drug class Antihypertensive

Headache 

(2014): Chaturvedi S+, Cochrane Database Syst Rev 2, CD008117 [REVIEW]Pediatric

Vertigo / dizziness 

(2014): Chaturvedi S+, Cochrane Database Syst Rev 2, CD008117 [REVIEW]Pediatric

Upper respiratory tract infection 

(2014): Chaturvedi S+, Cochrane Database Syst Rev 2, CD008117 [REVIEW]Pediatric

Adverse effects 

(2015): Drago F+, Int J Clin Pharm 37(5), 739

Adverse reactions attributed to entire drug class Endothelin receptor (ETR) antagonist

Facial edema 

(2009): Minniti CP+, Br J Haematol 147(5), 737 (2 cases)

Peripheral edema (see also edema) 

(2009): Minniti CP+, Br J Haematol 147(5), 737 (5 cases) (increased)

Rash 

(2009): Minniti CP+, Br J Haematol 147(5), 737 (2 cases)

Headache 

(2009): Minniti CP+, Br J Haematol 147(5), 737 (3 cases)

Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top